Vascular endothelial growth factor pathway

Journal of Thoracic Oncology

Volumn 4, Issue 11 SUPPL. 3, 2009, Pages

  Krupitskaya, Yelena ^a   Wakelee, Heather ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADNECTIN; AXITINIB; BEVACIZUMAB; BIBF 1120; CALGB 30704; CARBOPLATIN; CEDIRANIB; CISPLATIN; DOCETAXEL; E4599; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; XL 647;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; GENE MUTATION; HEMATOLOGIC DISEASE; HOARSENESS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MYALGIA; NAUSEA; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RASH; VOMITING;

EID: 73549089701     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000361755.32660.a1     Document Type: Conference Paper

References (10)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
2. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
3. Roskoski R Jr. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 2008;375:287-291.
4. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39: 469-478.
5. Karkkainen MJ, Alitalo K. Lymphatic endothelial regulation, lymphoedema, and lymph node metastasis. Semin Cell Dev Biol 2002; 13:9-18.
6. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005;15: 102-111.
7. Wheatley-Price P, Shepherd FA, Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 2008;3:1173-1184.
8. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234.
9. Akerley W, Langer CJ, Oh Y, et al. Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer. J Clin Oncol 2008;26:8043.
10. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-1412.